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Hepatocellular carcinoma �HCC�� is t�e fift� most 
common cancer and t�e fourt� leading cause of 
cancer related mortality worldwide�� wit� t�e �ig�est 
incidence in Asia�� w�ere �epatitis B or C is epidemic 
[1]. Alt�oug� t�e clinical diagnosis and management 
of early-stage HCC �as significantly improved�� HCC 
prognosis remains poor. Only 1����% of patients 
qualify for curative surgery [�]. T�e median survival 
of patients w�o �ave unresectable tumors is only 
4 mont�s [�]. Currently�� no effective systemic �c�e-
mot�erapeutic or c�emopreventive�� treatments are 
available. Hence�� investigating HCC pat�ogenesis and 
finding new treatment strategies is an urgent need.
T�e cyclooxygenase-� �COX-��� is �ig�ly expressed 
in a variety of �uman cancers [4�� 5]. COX-� �as been 
associated wit� tumor growt��� angiogenesis�� invasion�� 
and metastasis [6�� ��]. Overexpression of COX-� may 
increase t�e resistance of cancer cells to apoptosis 
[8]. T�us�� t�e reduction of t�e COX-� enzyme activity 
or protein expression may in�ibit cell growt� in cancer 
cells. Non-steroidal anti-inflammatory drugs �NSAIDs�� 
�ave been s�own to in�ibit COX enzymes and may be 
employed for t�e c�emoprevention of cancer [��� 1�]. 
Some NSAIDs suc� as nimesulide ex�ibit �ig� selectiv-
ity for COX-� enzyme�� but �ave little effects on COX-1 
enzyme [11]. T�e expression pattern of COX-� protein 
in HCC is well correlated wit� t�e differentiation grade�� 
suggesting t�at abnormal COX-� expression plays an 
important role in �epatocarcinogenesis [1��� 1�]. In�ibi-
tion of COX-� by several in�ibitors including celecoxib�� 
NS-��8 and nimesulide induces growt� in�ibition and 
marked apoptosis in cultured HCC cells by various 
mec�anisms [1��� 14���]. 
T�ere is also evidence suggesting an important 
role of angiogenesis in COX-�-mediated �epatocar-
cinogenesis. COX-� �as been s�own to induce angio-
genesis via vascular endot�elial growt� factor �VEGF���� 
a well-studied regulator of pat�ological angiogenesis 
[�1���]. Several recent studies s�ow t�at elevated 
COX-� expression correlates wit� increased VEGF level 
and microvascular density in �uman HCCs [16�� �4�� 
�5]. In cultured �epatocellular carcinoma cells�� VEGF 
production is increased by overexpression of COX-� 
or by treatment wit� prostaglandin E� �PGE����� and t�is 
effect is blocked by in�ibition of COX-� [16]. A separate 
study also s�ows a role for PGE� in t�e up-regulation 
of VEGF in t�e �epatocellular carcinoma cells [16]. 
T�ese findings suggest t�at COX-� and COX-�-derived 
PGE� signaling may promote �epatocarcinogenesis 
in part t�roug� VEGF-induced angiogenesis. In t�is 
regard�� targeting COX-�-derived prostaglandin sig-
naling represents a promising strategy to reduce t�e 
tumor burden. 
Doxorubicin is one of t�e effective agents for t�e 
treatment of patients wit� unresectable HCCs [�6�� ���]. 
Single use of doxorubicin yields response rate of up to 
��%�� �owever median survival is not prolonged. T�ere 
is no convincing evidence from randomized trails t�at 
t�e combination c�emot�erapy prolongs t�e survival 
of patients wit� unresectable HCC better t�an single 
agents. W�et�er COX-� in�ibitors are beneficial in t�e 
treatment of HCC if given in combination wit� t�ese 
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effective agents suc� as doxorubicin wit� comple-
mentary mec�anisms remains unknown.
In t�is study�� we �ave c�aracterized t�e effects of 
COX-� in�ibition on cell growt� and survival by treat-
ment wit� nimesulide�� a COX-� specific in�ibitor�� in 
�epatocellular carcinoma cell line HepG�. Our results 
s�owed t�at t�e treatment wit� nimesulide en�anced 
doxorubicin-mediated cytotoxicity and reduced pro-
duction of PGE� and VEGF. Our results t�at s�ow addi-
tive in�ibitory effects of COX-� in�ibitor nimesulide and 
doxorubicin on t�e growt� of �epatocellular carcinoma 
cells may provide t�e rationale for clinical studies of 
COX-� in�ibitors on t�e treatment or c�emopreven-
tion of HCC. 
MATERIALS AND METHODS
Reagents. Human HepG� �epatocellular carci-
noma cell line was obtained from T�e Researc� Insti-
tute on Hepatoma of S�ang�ai. R�PI 164��� D�E� 
and �E� culture medium was purc�ased from Gibco 
BRL. Fetal bovine serum �FBS�� was provided by Sijiqing 
Biological Engineering �aterial �Hangz�ou�� C�ina��. 
Rabbit anti-COX-� was from Cayman. S�eep anti-
rabbit�� s�eep anti-mouse secondary antibodies were 
purc�ased from Santa Cruz Biotec�nology�� Inc. �Santa 
Cruz�� CA��. �-�4�� 5-Dimet�ylt�iazol-�-yl��-��� 5-dip�en-
yltetrazolium bromide ��TT���� nimesulide and acridine 
orange �AO�� were purc�ased from Sigma C�emical Co. 
�St. Louis�� �O��. Doxorubicin was provided by Wanle 
Co. �S�enz�en�� C�ina��.
Cell culture. HepG� cells were maintained in 
D�E� medium supplemented wit� 1�% fetal bovine 
serum �FBS���� 1�� units/ml penicillin�� and 1�� mg/ml 
streptomycin. HepG� cells were cultured at 5% CO� 
and ���° C in a �umidified incubator �Nacpo-61���� 
DuPont Company�� USA��.
MTT assay. T�e number of viable cells was deter-
mined by �TT assay. Eac� cell sample was plated at 
a density of 1�4 cells/well in �6-well cluster dis�es for 
�4 � before treatment. T�en t�e medium was c�anged 
and nimesulide and doxorubicin were added in various 
concentrations and analyzed at indicated time points. 
After addition of �TT solution �5 g/L�� in eac� well�� t�e 
cells were incubated at ���° for 4 ��� and t�en 15� µL 
D�SO was added to dissolve t�e dark blue crystals. 
T�e absorbance was measured in an ELISA plate 
reader �EL��1 Strip reader�� BIOTEK�� USA�� wit� a test 
wavelengt� of 5��� nm�� and t�e relative percentage of 
survival was calculated by dividing t�e absorbance of 
treated cells by t�at of t�e control in eac� experiment. 
Percent cytotoxicity was calculated using t�e formula: 
percent cytotoxicity = [1-�absorbance of experimental 
wells/absorbance of control wells��] × 1��%.
Cell morphology. After treatement wit� drugs�� 
cytological morp�ology c�anges were observed under 
t�e Olympus optical microscope. Cells were subcul-
tured on coverslips in 6-well culture plates. After �4 ��� 
t�e coverslips were taken out and stained wit� acridine 
orange. Cells were observed and p�otograp�s were 
taken under fluorescence microscope.
Flow cytometry. HepG� cells were seeded in cul-
ture flasks. T�e culture bottles were divided into one 
medium alone and t�ree drug-treated groups. Eac� 
group was in triplicate. W�en t�e cells were anc�ored 
to t�e plates�� various drugs were added and t�e cells 
incubated at ���°�� 5% CO� for 48 �. T�en eac� group 
of cells were was�ed wit� PBS�� trypsinized and t�en 
stained wit� propidium iodide �PI�� Sigma�� USA��. T�e 
red fluorescence of DNA-bound PI in eac� group was 
measured at 488 nm by FACScan flow cytometry 
�EPTCS XLL��CL Beckman Coulter�� UK��.
Western blot analysis. For immunoblot analysis 
of COX-��� HepG� cells were lysed in a buffer consisting 
of 5� m� Tris-HCl�� pH ��.4�� 1% Tween ���� � m� EDTA�� 
1 m� p�enylmet�ylsulfonyl fluoride�� 1� µg/mL aprotinin�� 
and 1� µg/mL leupeptin. Debris was removed by centrifu-
gation �Beckman GPKR mac�ine�� at ������ g for �� min 
at 4 °C. A total of 6� µg of precipitated and denatured 
protein was separated by 1�% sodium dodecyl sulfate-
polyacrylamide gel electrop�oresis �SDS-PAGE�� and 
transferred electrop�oretically to polyvinylidene fuoride 
membranes �Immun-Blot PVDF membrane�� �.� µm; 
Bio-Rad��. �embranes were blocked wit� 5% nonfat milk 
powder in �.5 % Tween ��-PBS for � �. Primary antibod-
ies to COX-� were used at a final dilution of 1 : 1��� for 
overnig�t�� at  4 °C. T�e blot was was�ed several times wit� 
�.�5% Tween ��-PBS and incubated wit� t�e appropri-
ate goat anti-rabbit antibody for � �. Immunodetection 
was carried out using en�anced c�emiluminescence 
reagent following t�e manufacturer’s instructions �Pierce 
Biotec�nology Inc�� USA��. 
Measurement of prostaglandin E2 and VEGF 
production. HepG� carcinoma cells were plated at a 
density of 5 × 1�5 cells / p6� Petri dis� in complete D�E� 
medium for 1� �. HepG� cells were treated wit� �5�
1�� µ� nimesulide for �4 �. After drug treatment�� cul-
ture supernatant was collected and centrifuged briefly. 
T�e amount of PGE� in t�e medium was measured using 
a commercial RIA kit �Wu�an Boster Co�� Wu�an�� C�ina�� 
and VEGF level determined wit� an enzyme-linked im-
munosorbent assay �ELISA�� kit �Promega Corporation�� 
following t�e manufacturer’s instructions.
Statistical analysis. Data from t�e popula-
tion of cells treated wit� different conditions were 
analyzed using paired Student’s t-test or ANOVA test 
�a comparison of multiple groups���� and p value of 
< �.�5 was considered statistically significant in t�e 
experiments.
RESULTS
Nimesulide inhibits the COX-2 activity in HepG2 
hepatocellular carcinoma cells. First�� we performed 
t�e Western blot analysis to examine w�et�er COX-� 
protein is expressed in HepG�cells. As s�own in Fig. 1�� a�� 
COX-� protein was �ig�ly expressed in HepG� cells. T�is 
is consistent to a recent immuno�itoc�emistry study 
t�at s�ows �ig� COX-� protein expression in HepG� 
and Hu��� cells [�8]. As treatment wit� �5�1�� µ� 
nimesulide for �4 � did not significantly alter expression 
levels of COX-� protein in HepG� cells �Fig. 1�� a���� next 
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we tested w�et�er treatment wit� nimesulide in�ibits 
t�e COX-� enzyme activity by measuring PGE� levels 
of culture supernatant. T�e average amount of PGE� in 
t�e medium alone controls from t�ree independent ex-
periments was �.65 ng/ml. Compared wit� t�e control�� 
t�e PGE� production was reduced by about 8�%�� 65% 
and 4�% �4 � after t�e treatment wit� �5 µ��� 5� µ� or 
1�� µ� of nimesulide�� respectively �Fig. 1�� b���� indicating 
t�e dose-dependent in�ibition. 
Fig.1. Effects of nimesulide on t�e COX-� protein expression 
and PGE� production in �uman HepG� cells. �a�� HepG� cells 
were treated wit� �5�1�� µ� nimesulide for �4 � as indicated. 
T�e total protein extracts were subjected to Western blot analysis 
using anti-COX-� antibody. Anti-ERK-� antibody was used as a 
loading control. �b�� T�e HepG� cells were treated wit� �5�1�� µ� 
nimesulide. After incubation for �4 ��� t�e PGE� level in t�e 
culture medium was measured by a PGE� EIA kit following t�e 
manufacturer’s protocol. T�e means ± S.E of t�ree independent 
experiments in eac� treatment are s�own
Nimesulide inhibits cell growth and enhances 
doxorubicin-mediated apoptosis of cultured 
HepG2 cells. To determine w�et�er COX-� in�ibi-
tion by nimesulide contributes to growt� in�ibition of 
HepG� cells we measured t�e number of apoptotic 
cells after treatment wit� various doses of nimesulide 
by �TT assay. As s�own in t�e left panel of Fig. ��� a�� 
t�e number of viable cells started to decline by treat-
ment wit� a low concentration of nimesulide ��5 µ��� 
and continued to drop by up to 4�% at 4�� µ� of 
nimesulide. As expected�� cell apoptosis induced by 
doxorubicin is more evident t�an t�at by nimesulide as 
treatment wit� 8� µ� of doxorubicin induced deat� of 
almost all cells in t�e culture �Fig. ��� a�� rig�t panel��. T�e 
apoptosis triggered by nimesulide or doxorubicin was 
s�own in a concentration-dependent manner. 
Because nimesulide-induced cell deat� is t�roug� 
COX-� in�ibition and doxorubicin acts as cell cycle 
in�ibitor on triggering cell apoptosis�� we �ypot�esize 
t�at t�e in�ibition of COX-� by nimesulide may en-
�ance t�e doxorubicin-mediated cytotoxity. To test t�is 
possibility�� we performed t�e �TT assay by co-treat-
ment of HepG� cells wit� doxorubicin and nimesulide. 
As s�own in Fig. ��� b�� compared to cell treated wit� 
5 µ� of doxorubicin alone�� addition of �5�� 5� or 1�� µ� 
nimesulide yielded a � to �.5 fold increase in cell deat��� 
respectively. T�is synergistic effect of nimesulide 
persisted even at �ig�er concentrations of doxorubi-
cin�� 1� µ� or �� µ�. Since treatment wit� more t�an 
4� µ� of doxorubicin alone already induced apoptosis 
of most cells�� an increase in doxorubicin-mediated 
cytotoxity of HepG� cells by addition of nimesulide 
was limited �Fig. ��� b�� rig�t two panels��.
Fig. 2. Co-treatment of nimesulide and doxorubicin additively 
in�ibited t�e growt� of HepG� cells. �a�� T�e cells were treated 
wit� indicated �5�4�� µ� nimesulide or indicated 5�8� µ� 
of doxorubicin for �4 �. T�e cell survival was measured by �TT 
assay. Results were obtained from � independent experiments 
and t�e bar represents S.E. Significant c�anges between un-
treated and treated samples are marked by asterisks: *p < �.�5 
and **p < �.�1. �b�� T�e cells were co-treated wit� 5�8� µ� 
doxorubicin alone or toget�er wit� �5�1�� µ� nimesulide for 
�4 �. T�en t�e cell survival was measured by �TT assay. Results 
were obtained from 4 independent experiments and t�e bar 
represents t�e S.E. Significant c�anges between doxorubicin 
alone and co-treatment wit� nimesulide samples are marked 
by asterisks: *p < �.�5
To furt�er confirm t�e cytotoxic synergy between 
nimesulide and doxorubicin we performed morp�ol-
ogy study by staining cells wit� acridine orange. We 
observed t�e normal morp�ology of drug-untreated 
HepG� cells: s�ape of tri- or multi-angles wit� abundant 
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cytoplasma�� and large oval nuclei wit� dispersed c�ro-
matin �Fig. ��� a�� left panel��. �4 � after treatment wit� 1�� 
µ� of nimesulide and 1� µ� of doxorubicin�� HepG� 
cells ex�ibited t�e typical morp�ology of apoptotic 
cells�� including cell s�rinkage�� deep-dyed pyknotic 
nuclei�� margination of nuclear c�romatin�� cytoplasmic 
blebbing and clusters of apoptotic bodies �Fig. ��� a�� 
rig�t panel��. Also�� we measured t�e DNA content by 
propidium iodide �PI�� staining�� and cell apoptosis was 
reflected by t�e appearance of a cell population wit� 
subdiploid and pre-G1p�ase t�roug� flow cytometric 
analysis. Consistent wit� �TT assay�� addition of 1�� µ� 
of nimesulide significantly increased a portion of sub-
diploid and pre-G1 p�ase ��1.��%�� compared to t�at of 
doxorubicin alone group �1�.6%�� �Fig. ��� b�� bottom two 
panels��. By contrast�� a muc� smaller portion of pre-G1 
p�ase was s�own in t�e cells treated wit� nimesulide 
alone �Fig. ��� b�� rig�t top panel��.
Fig. 3. Co-treatment of nimesulide and doxorubicin en�anced 
apoptosis induction of HepG� cells. �a�� T�e HepG� cells were 
treated wit� or wit�out nimesulide 1�� µ� and doxorubicin 1� µ� 
for �4 � and stained wit� acridine orange. T�e cell morp�ology 
was observed under fluorescent microscope. �b�� Flow cytometry 
analysis of DNA content of HepG� cells after treated wit� 1�� µ� 
of nimesulide and/or �� µ� of doxorubicin for �4 �. Represen-
tative DNA �istograms were from � independent experiments. 
T�e percentage of pre-G1 p�ase at various culture conditions 
is indicated 
Co-treatment with doxorubicin and nimesulide 
reduces production of VEGF in HepG2 cells. VEGF�� 
one of t�e most potent angiogenic factors�� �as been 
s�own to play a pivotal role in tumor angiogenesis�� in-
cluding HCC. A line of evidence reveals t�at t�e elevated 
COX-� expression correlates wit� increased VEGF level 
and microvascular density in �uman HCCs [16�� �4�� �5]. 
However�� it is not known w�et�er t�e in�ibition of COX-� 
reduces VEGF production in �epatocellular carcinoma 
cells. To test t�is possibility�� we treated HepG� cells 
wit� �5 µ� or 5� µ� of nimesulide and measured VEGF 
levels in t�e culture supernatants by an ELISA. As s�own 
in Fig. 4�� treatment wit� 5� µ� of nimesulide alone led to 
an about � fold reduction in VEGF levels and t�is effect 
was largely augmented by addition of 5 µ� or 1� µ� 
of doxorubicin. VEGF production was also significantly 
reduced if t�e cells were co-treated wit� doxorubicin 
and a lower concentration ��5 µ��� of nimesulide�� sug-
gesting t�e synergistic in�ibition of VEGF production in 
HepG� cells by two agents.
Fig. 4. Co-treatment wit� nimesulide and doxorubicin reduced 
VEGF production of cultured HepG� cells. T�e cells were co-
treated wit� 5�1� µ� doxorubicin and �5�5� µ� nimesulide for 
48 �. T�e VEGF levels were determined in culture supernatants by 
ELISA following t�e manufacturer’s protocol. VEGF secretion was 
significantly reduced in t�e co-treatment group compared wit� 
t�e single nimesulide or doxorubicin treated group �*p < �.�5��
DISCUSSION
Doxorubicin is one of t�e most often used drugs for 
treatment of HCC and single use of doxorubicin yields 
response rate of about ��% for unresectable tumors. 
However�� t�ere is no convincing evidence t�at t�e use 
of doxorubicin improves t�e prognosis of patients wit� 
HCC�� t�erefore t�e effect of t�is drug on HCC is still 
limited [�����]. NSAIDs�� suc� as aspirin�� indomet�a-
cin and sulindac�� may play a role in t�e in�ibition of 
proliferation and induction of apoptosis in tumor cells 
t�roug� t�e in�ibition of COX-� activity [����5]. T�e 
anti-inflammatory and anti-angiogenic effects of 
NSAIDs �ave been explored for t�e cancer t�erapy and 
some of t�ese agents are currently under clinical trials 
[�6�� ���]. Nimesulide�� a specific COX-� in�ibitor�� can 
bind specifically to t�e large catalytic moiety of COX-��� 
wit� muc� less adverse effects on t�e gastrointestinal 
tract compared to t�e non-specific NSAIDs. A selective 
COX-� in�ibitor JTE-5�� �as been reported to en�ance 
cytotoxity in bladder cancer wit� 5-fluorouracil [�8]. 
A combination of common antitumor drugs and COX-� 
in�ibitors may en�ance c�emot�erapeutic efficacy�� 
reduce drug dose and adverse side effects. It �as been 
s�own t�at nimesulide in�ibits t�e growt� of �uman 
�epatoma cell line S��C-�����1 in vitro [1��]. However�� 
studies on t�e combination of selective COX-� in�ibi-
tors including nimesulide and common c�emot�erapy 
agents against �uman �epatocellular carcinoma are 
not documented. In t�is study�� we investigated t�e 
effects of a combination of nimesulide and doxorubi-
cin on t�e growt� in�ibition in �uman �epatocellular 
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carcinoma HepG� cells. Our results s�owed t�at treat-
ment of nimesulide significantly in�ibited cell growt� in 
HepG� cells. �oreover�� t�e combination of doxorubi-
cin and nimesulide additively increased t�e cytotoxicity 
and growt� in�ibition in HepG� cells. T�erefore�� our 
results suggest t�at t�e use of COX-� in�ibitors may 
be beneficial w�en combined wit� doxorubicin for t�e 
treatment of patients wit� HCC.
Prostaglandins�� including PGE��� synt�esized by 
COX enzymes�� are reported to increase cell growt� 
and induce proliferation in t�e cultured rat �epatocytes 
[���� 4�]. In �uman �epatocellular carcinoma cells�� 
treatment wit� prostaglandin E� �PGE��� increases VEGF 
production and t�is effect is blocked by in�ibition of 
COX-��� suggesting a link of COX-� wit� VEGF signaling 
in �epatocarcinogenesis [16]. In support of t�ese find-
ings�� we �ave observed t�e �ig� expression of COX-� 
protein in HepG� cells and in�ibition of COX-� by nime-
sulide led to reduced production of PGE� and VEGF�� 
and decreased viable cells in t�e culture. T�erefore�� 
t�e interplay between COX-�-derived prostaglandin 
signaling and ot�er growt�-regulatory pat�ways suc� 
as VEGF is expected to provide important t�erapeutic 
implications.
Apoptosis is an important p�ysiological process 
t�at prevents t�e formation of tumor clone and t�e 
failures of apoptosis lead to t�e development of many 
tumors including �epatocellular carcinoma [41]. T�e 
recent reports �ave demonstrated t�at NSAIDs induce 
apoptosis in different tumor cells [1��� 4�]. It is also 
conceivable t�at apoptosis mig�t occur in t�e �uman 
�epatocellular carcinoma cells in response to nime-
sulide. To evaluate t�e role of nimesulide in cell apop-
tosis�� we cultured HepG� cells and treated cells wit� 
various concentrations of nimesulide or toget�er wit� 
a low concentration of doxorubicin. Flow cytometry 
analysis of sub-diploid peak of DNA content revealed 
t�e ability of nimesulide to trigger apoptosis in HepG� 
cells at t�ese concentrations t�at were sufficient to 
in�ibit cell proliferation. In addition�� t�e nimesulide-in-
duced apoptosis is significantly increased by addition 
of a low concentration of doxorubicin. T�us�� apoptosis 
may be one of t�e mec�anisms for nimesulide to in�ibit 
cell growt� in HepG� cells�� especially w�en nimesulide 
is combined wit� doxorubicin.
In patients wit� �epatocellular carcinoma�� �y-
pervascularity correlated wit� t�e over-expression 
of VEGF and significantly associated wit� t�e tumor 
extension and s�orter median survival time [�5�� 4��� 
44]. Prostaglandin E� increases t�e expression and 
t�e secretion of VEGF in �epatocellular carcinoma 
cells [16�� 45]. We found t�at t�e in�ibition of COX-� by 
nimesulide reduced VEGF production in HepG� cells. 
Interestedly�� treatment of doxorubicin also in�ibited 
VEGF secretion by HepG� cells�� and co-treatment of 
doxorubicin and nimesulide markedly decreased t�e 
levels of VEGF in cultured supernatants. Toget�er�� our 
data suggest t�at co-treatment wit� doxorubicin and 
nimesulide induces growt� in�ibition and cell deat� 
in part t�roug� t�e in�ibition of VEGF production in 
HepG� cells. However�� t�e precise mec�anism of t�e 
in�ibition of VEGF production in t�is situation needs 
furt�er investigation.
T�is study for t�e first time presents evidence 
t�at a combination of COX-� in�ibitor nimesulide and 
doxorubicin additively in�ibits growt� of t�e �uman 
�epatocellular carcinoma cells. T�is effect was mainly 
observed owing to increased apoptosis and reduced 
VEGF production. T�e study provides a new strategy 
t�at t�e combination of COX-� in�ibitors and doxo-
rubicin may be effective in t�e treatment of �uman 
�epatocellular carcinoma.
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КОМБИНИРОВАННОЕ ПРИМЕНЕНИЕ ИНГИБИТОРА 
ЦИКЛООКСИГЕНАЗЫ-2 И ДОКСОРУБИЦИНА 
ПРИВОДИТ К УГНЕТЕНИЮ РОСТА И АПОПТОЗУ КЛЕТОК 
ГЕПАТОКАРЦИНОМЫ ЧЕЛОВЕКА
Угнетение циклооксигеназы-2 (ЦОГ-2) оказывает терапевтический эффект при лечении больных с солидными опухолями 
и сопровождается снижением пролиферации опухолевых клеток и индукцией апоптоза. Цель: изучение роли ингибито-
ра ЦОГ-2 — нимесулида в процессах роста и апоптоза культивированных клеток гепатокарциномы человека HepG2. 
Методы: для оценки апоптоза и угнетения роста клеток при применении нимесулида самостоятельно и в сочетании с 
доксорубицином применяли MTT-анализ, проточную цитометрию и стандартные морфологические методы. Результаты: 
установлено, что обработка клеток HepG2 cells нимесулидом  в концентрации > 50 μM приводила к угнетению активности 
ЦОГ-2 за счет снижения продукции PGE2, после чего отмечали подавление роста и апоптоз клеток при неизмененном 
уровне экспрессии ЦОГ-2. Комбинированное применение 50 μM или 100 μM нимесулида и доксорубицина в концентра-
ции 5–20 μM обусловило усиленное угнетение роста клеток, индукции апоптоза и снижение продукции VEGF. Выводы: 
полученные данные свидетельствуют о синергическом и/или аддитивном эффекте при применении ингибиторов ЦОГ-2 
и химиотерапевтических препаратов.
Ключевые слова: гепатокарцинома, нимесулид, ЦОГ-2, доксорубицин, апоптоз, VEGF. 
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